Introduction
The burden of psychiatric disorders in the HIV-infected population exceeds that of the general US population (Bing et al., 2001; Pence, Miller, Whetten, Eron, & Gaynes, 2006) and the 12-month prevalence of psychiatric disorders is estimated at 48% (Bing et al., 2001) . This estimate is nearly two times greater than the 26% prevalence rate estimated in the general population (Kessler, Chiu, Demler, Merikangas, & Walters, 2005) . The most commonly detected psychiatric disorders in the HIV-infected population include major depression, dysthymia and generalised anxiety disorder (Bing et al., 2001) . Additionally, patients who suffer from psychiatric disorders are likely afflicted with symptoms of insomnia (Karaz, 2010) . The estimated prevalence rate for anxiety disorders may be as high as 38% (Elliott, 1998) , 32% for depression (Bing et al., 2001) and 78% for insomnia (Rubinstein & Selwyn, 1998) , in the HIV-infected population. Each of these estimates exceeds those of the general population: 18% for anxiety (Kessler et al., 2005) , 7% for depression (Kessler et al., 2003) and 30% for insomnia (Roth, 2007) . Managing symptoms of these comorbidities is especially important in HIV-infected patients as they are associated with suboptimal adherence to antiretrovirals (Ammassari et al., 2001; Pence et al., 2006) . High levels of adherence are necessary to achieve optimal viral load suppression and mitigate the development of drug-resistant HIV infection (Bangsberg et al., 2000; Paterson et al., 2000) .
Benzodiazepines are the most frequently used psychotropic drug class (Paulose-Ram, Jonas, Orwig, & Safran, 2004) , and are widely prescribed for the management of symptoms related to anxiety, insomnia and depression (Shader, Greenblatt, & Balter, 1991; Valenstein et al., 2004) . Concerns exist regarding benzodiazepine use in the HIV-infected population due to potential interactions with antiretroviral therapy (Ferrando & Wapenyi, 2002; Greenblatt et al., 2000) . Moreover, due to their abuse/misuse potential, benzodiazepines are not recommended for patients with a substance abuse history, a common problem among the HIV-infected population (Bing et al., 2001) . To date, few studies have compared the prevalence of benzodiazepine use in the HIV-infected and uninfected populations. Furthermore, no studies have examined benzodiazepine usage by sex despite evidence suggesting prevalence rates of psychiatric disorders differ between males and females in the general and HIV-infected populations (Kessler et al., 2003; Lopes et al., 2012; Vesga-López et al., 2008) . The current study uses insurance claims data to examine whether HIV-infected patients are more likely to fill a benzodiazepine prescription than uninfected patients, and investigate sex differences in the likelihood of filling a benzodiazepine prescription among HIV-infected and uninfected patients.
Methods
We established a four-state nationally representative, population-based cohort using data from a large private insurance claims database from January 2007 to December 2009. This claims that database includes patient socio-demographics and codes related to interactions with the health care system. Beneficiaries were included if they resided in Kentucky, Maryland, North Carolina or Washington, between 19 and 64 years of age, and had at least one health care claim in 2007 followed by a subsequent claim in either 2008 or 2009. Beneficiaries were identified as HIV positive if they had at least one health care claim in 2007 with the ICD-9 code "042" [Human Immunodeficiency Virus (HIV) disease]. The outcome of interest was filling a benzodiazepine prescription. Benzodiazepine fills during the study period were represented by a claim for any benzodiazepine identified using national drug codes. We considered the following covariates assessed in the year 2007: sex, age, race, education, state of residence, continuous insurance enrollment, substance abuse treatment (e.g., residential or non-residential treatment facility) and psychiatric disorders. Bivariate analysis examined the association between HIV-infection and benzodiazepine use. Multivariate logistic regression models adjusted for covariates identified above were used to estimate the adjusted odds ratio (AOR) of filling a benzodiazepine prescription for HIV-infected patients. We examined the presence of interaction between HIV infection and the covariates using backwards elimination. Statistical significance was considered using the Wald χ 2 p-value associated with the interaction term as well as clinically meaningful differences by comparing stratum-specific OR. Data use was approved by the University of Kentucky Institutional Review Board. Statistical analysis was conducted using Stata 12.0 (StataCorp., College Station, TX).
Results
A total of 323,902 beneficiaries met the inclusion criteria for this study. Of these beneficiaries 106 were excluded due to duplicate or conflicting information. Overall, our study cohort consisted of 323,796 beneficiaries, 723 were identified as HIV infected. Baseline characteristics and benzodiazepine utilisation for HIVinfected and uninfected patients are shown in Table 1 . Compared to the uninfected population the HIVinfected population had a greater proportion of men (80% vs. 44%) and blacks (21% vs. 7%). The HIVinfected population also had a greater proportion of patients with a diagnosis of depression (12% vs. 8%) or insomnia (6% vs. 3%). We observed a greater proportion of HIV-infected patients filled a benzodiazepine prescription during the study period (24% vs. 19%) with alprazolam, diazepam and lorazepam being the most commonly filled benzodiazepines. Figure 1 shows the AOR of filling a benzodiazepine prescription for HIV-infected patients stratified by sex relative to the overall estimate of HIV-infected patients. The overall AOR demonstrates that without stratifying by sex, HIV-infected patients have 1.68 times greater odds of filling a benzodiazepine prescription than uninfected patients (95% CI: 1.39, 2.02). When stratified by sex, results from the multivariate regression showed that HIV-infected males are 1.68 times more likely to fill a benzodiazepine prescription than uninfected males, adjusting for covariates (95% CI: 1.05, 2.67), while no statistical difference was observed between HIV-infected and uninfected females (AOR: 1.12, 95% CI: 0.73, 1.70). Interaction between HIV infection and age, race, education, substance abuse treatment and psychiatric disorders was considered but statistical significance was not achieved at the 0.05 level nor were there any clinically meaningful differences between the strata.
In the overall population the likelihood of filing a benzodiazepine prescription is influenced by the patient's age, sex and race, along with treatment for substance abuse and psychiatric disorder diagnosis. With each additional 10 years, patients age, their odds of filling a benzodiazepine prescription increase by 21% (AOR: 1.21, 95% CI: 1.20, 1.22). Additionally, males are less likely than females (AOR: 0.62, 95% CI: 0.61, 0.63) and non-white patients are less likely than white patients to fill a benzodiazepine prescription (AOR: 0.72, 95% CI: 0.70, 0.74). Furthermore, treatment for substance abuse (AOR: 1.27, 95% CI: 1.14, 1.42), or having a diagnosis of anxiety (AOR: 5.99, 95% CI: 5.81, 6.18), depression (AOR: 2.48, 95% CI: 2.42, 2.56), or insomnia (AOR: 2.78, 95% CI: 2.65, 2.90) increases the odds of filling a benzodiazepine prescription. 
Discussions
This study demonstrates that HIV-infected patients are more likely to fill a benzodiazepine prescription than uninfected patients. Furthermore, we show HIV-infected males are more likely than uninfected males to fill a benzodiazepine prescription, with no observed difference between HIV-infected and uninfected females. This difference is notable as concerns exist regarding benzodiazepine use in the HIV-infected population due to their high abuse/misuse potential and the link between substance abuse and poor medication adherence (Arnsten et al., 2002; Singh et al., 1996) . The overall difference in the odds of filling a benzodiazepine prescription between HIV-infected and uninfected patients may be related to the high prevalence of psychiatric disorders in this population (Bing et al., 2001) . However, we adjusted for these conditions in our models suggesting additional factors shown to be associated with benzodiazepine use in this population and not captured within claims data, such as exposure to stressful events related to HIV serostatus and disclosure (Roux et al., 2011) , may explain the differences in benzodiazepine use between the HIV-infected and uninfected populations. The high prevalence of substance abuse and dependence in the HIV-infected population (Bing et al., 2001) should also be considered as an explanation of the observed differences in benzodiazepine use. Few studies have compared benzodiazepine use in the HIVinfected and uninfected populations and to our knowledge, this study is the first to examine differences in receipt of benzodiazepines by sex. Roux et al. (2011) investigated factors associated with regular benzodiazepine use in HIV-infected patients but as this study included HIV-infected patients only, comparisons to the uninfected population were not made (Roux et al., 2011) .
Reasons for observed differences between males and females in our study may be related to underlying differences in the prevalence of psychiatric disorders, differences in stigmatisation, as well as differences in overall health care utilisation between HIV-infected men and women. Lopes et al. (2012) showed that HIVinfected men were more likely than uninfected men to have a specific Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis with no observed differences among women. Our results support these findings as we found HIV-infected men were more likely than uninfected men to fill a benzodiazepine prescription, with no observable differences between women. Additionally, Roux et al. (2011) found that individuals belonging to the injecting drug use (IDU) and men who have sex with men (MSM) HIVtransmission groups were more likely than their heterosexual HIV-transmission group counterparts to report regular benzodiazepine use. This finding is likely associated with IDUs and MSM group members perceiving and facing greater discrimination and stigmatisation (Herek, Capitanio, & Widaman, 2003) . Evidence exists of differences in health care utilisation between HIV-infected men and women. Hellinger and Encinosa (2004) found that HIV-infected men were more likely than HIV-infected women to receive antiretroviral therapy and costlier medications.
Limitations to this study exist. First, this study uses data from a private insurance claims database for four states, and may not accurately represent the overall HIVinfected or uninfected populations. Also, this study does not account for the number of benzodiazepine prescriptions filled or the quantity and dosages of those prescriptions. Additionally, we cannot account for prescriptions acquired through family and friends or paid for using cash. Finally, while our results show that HIV-infected patients are more likely to fill a benzodiazepine prescription, we did not differentiate between appropriate and inappropriate use.
Despite these limitations, our findings demonstrate HIV-infected patients, especially HIV-infected males, are more likely to use benzodiazepines. Our findings, in combination with evidence demonstrating sex differences in psychiatric disorders, show the need for further research evaluating reasons for observed differences. Furthermore, intervention studies targeting this at-risk population to reduce the risk of substance abuse and improve HIV clinical care are warranted.
